Infinium Global Research Prostate Cancer Therapeutics Market | Page 2

A latest report has been added to the wide database of Prostate Cancer Therapeutics Market by Infinium Global Research.
This report studies the Prostate Cancer Therapeutics Market by Component (Hormonal therapy (LHRH antagonists, LHRH
agonists and Anti-androgen), (Chemotherapy, Immunotherapy, Radiation therapy) market status and outlook of global and
major regions, from manufacturers, and end industries. The objective of the study is to identify market sizes of different
segments & countries in recent years and to forecast the values for the next six years. Prostate Cancer Therapeutics Market
provides opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape,
latest trends, and product offerings of the major companies in the Prostate Cancer Therapeutics Market. According to the
report the Global Prostate Cancer Therapeutics Market is projected to grow at a CAGR of around 9.9% in terms of value over
the period of 2017-2023. Innovations in the development of new drugs and therapies, large number of new drugs entering
into the market with FDA approval, high growth in hormone-refractory prostate cancer therapeutics market, and rise in base
of aging population are the key driving factors for the growth of this market. In addition, rise in prevalence of prostate cancer,
changing lifestyle habits of populations, increased patient’s healthcare awareness, and increasing demand for non-invasive
therapies are further expected to propel the market growth in the coming years. Along with these driving factors, the market
for prostate cancer is facing some challenges such as time consuming regulatory compliance and high cost of prostate drugs.
However, the market for prostate cancer is likely to rise in the future due to the large number of ongoing innovations for the
treatment of prostate cancer.
Geographically, North America is the leading contributor to the market and is expected to retain its position during the
forecast period due to high awareness, large base of prostate cancer patients, rise in investments, and various initiatives by
government in the healthcare sector. However, Asia-Pacific market is expected to grow at a faster rate during the forecast
period. This is predominantly due to increased healthcare awareness, technological advancements, significant investments
and growing awareness among the population about the treatment options available in the market.
Companies profiled:
Abbott Laboratories
AstraZeneca plc
Astellas Pharma Inc.
Bristol-Myers Squibb
Johnson & Johnson
Pfizer Inc.
Infinium Global Research